oral poliovirus vaccine type 1 type 3 (human diploid cell)

Oral poliovirus vaccine type 1 type 3 (human diploid cell), also known as bOPV, is a live attenuated bivalent oral vaccine developed by the Beijing Institute of Biological Products (BIBP), a subsidiary of China National Biotec Group (CNBG). The vaccine contains live attenuated Sabin strains of poliovirus types 1 and 3 cultivated in human diploid cells (2BS strain). It is indicated for active immunization to prevent poliomyelitis, a highly infectious viral disease primarily affecting children under five years of age. Administered orally as drops, the vaccine induces both mucosal and systemic immunity against poliovirus serotypes 1 and 3. It was first approved in China in November 2015 and achieved WHO prequalification in December 2017, enabling its widespread distribution in international markets.

Other names

Bivalent Oral Poliovirus VaccinePoliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), OralPoliomyelitis Vaccine (live, oral attenuated, human Diploid Cell), type 1 and 3bOPVoral polio vaccine